This clinical trial focuses on patients with newly diagnosed grade 2 or 3 glioma, a type of brain tumor with specific genetic characteristics including 1p/19q co-deletion. The study aims to evaluate two different treatment approaches to improve patient outcomes.
The first treatment approach combines two chemotherapy drugs – temozolomide and lomustine – followed by radiation therapy to part of the brain and additional chemotherapy if the disease progresses. The second approach starts with radiation therapy followed by a combination of three chemotherapy drugs: procarbazine, lomustine, and vincristine (known as PCV chemotherapy), with additional treatment options if the disease progresses.
During the study, doctors will monitor how well patients function in their daily activities, their thinking abilities, and their quality of life. These factors, along with survival time, will help determine which treatment approach works better. The medications used in this study are given either by mouth as capsules or through an intravenous line directly into the bloodstream.
Germany 
